And to pin it down a little tighter, the article states:

"No clinical trials of BET inhibitors in COVID-19 have been initiated at the time of this publication, but several compounds have been advanced to the clinic for other indications such as cancer, including OTX015/MK-8628 highlighted in our study, and possess the potential to be quickly repurposed for COVID-19 (31). Although not formally initiated, Resverlogix has announced plans for a COVID-19 phase 2 clinical trial with their BET inhibitor, apabetalone, which was recently tested in a phase 3 study for cardiovascular disease (33)." (bolding added)

I believe this article was first published on Dec 11, 2020.

A question for the scientists on this Hub: How promising is Apabetalone when it comes to COVID 19? 

Koo